Cargando…
Synthetic Lethality Targeting Polθ
Research studies regarding synthetic lethality (SL) in human cells are primarily motivated by the potential of this phenomenon to be an effective, but at the same time, safe to the patient’s anti-cancer chemotherapy. Among the factors that are targets for the induction of the synthetic lethality eff...
Autores principales: | Drzewiecka, Małgorzata, Barszczewska-Pietraszek, Gabriela, Czarny, Piotr, Skorski, Tomasz, Śliwiński, Tomasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223150/ https://www.ncbi.nlm.nih.gov/pubmed/35741863 http://dx.doi.org/10.3390/genes13061101 |
Ejemplares similares
-
Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours
por: Barszczewska-Pietraszek, Gabriela, et al.
Publicado: (2022) -
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023) -
Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023) -
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019) -
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)